s6y

CITIUS ONCOLOGY, INC.

Ticker
CTOR
CIK
1851484
Industry
Pharmaceutical Preparations
Formerly
TenX Keane Acquisition

Financials 22

  1. 10-Q Quarterly Report for period ending Jun 30, 2026
  2. 10-Q Quarterly Report for period ending Mar 31, 2026
  3. 10-Q Quarterly Report for period ending Dec 31, 2025
  4. 10-K Annual Report for period ending Sep 30, 2025
  5. 10-Q Quarterly Report for period ending Jun 30, 2025
  6. 10-Q Quarterly Report for period ending Mar 31, 2025
  7. 10-Q Quarterly Report for period ending Dec 31, 2024
  8. 10-K/A Annual Report for period ending Sep 30, 2024
  9. 10-K Annual Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 22 financials filings

News 55

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 55 news filings

Ownership 97

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 97 ownership filings

Prospectus 41

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-3 Registration statement for specified transactions by certain issuers
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 41 prospectus filings

Proxies 12

  1. DEF 14A Definitive proxy statements
  2. DEF 14C Definitive information statements
  3. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  4. DEF 14C Definitive information statements
  5. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. DEFA14C Definitive additional information statement materials including Rule 14(a)(12) material
  8. DEF 14C Definitive information statements
  9. PRE 14C Preliminary information statement not related to a contested matter or merger/acquisition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 12 proxies filings

Other 53

  1. SCHEDULE 13G/A
  2. ARS Annual report to security holders
  3. SCHEDULE 13G/A
  4. EFFECT Notice of Effectiveness
  5. SCHEDULE 13D/A
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. UPLOAD Letter (PDF)
  8. SCHEDULE 13G/A
  9. EFFECT Notice of Effectiveness
  10. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing

All 53 other filings